Over 36 million individuals in the U.S. live with Type 2 diabetes. A significant portion, approximately 22 percent or around 8 million people, depend on daily insulin injections to manage their blood glucose levels.
This week marks a pivotal moment in diabetes care. Novo Nordisk is launching a groundbreaking weekly insulin dose option. This innovation aims to reduce the daily burden for those relying on insulin, offering enhanced convenience and fewer painful injections.
While the weekly dose introduces a more convenient regimen, it’s essential to note potential risks. One such risk includes hypoglycemia, which necessitates careful consideration and monitoring by patients and healthcare providers.
Leave a Reply